Obecabtagene Autoleucel Improves Survival in B-Cell Acute Leukemia
The Future of CAR T-Cell Therapy: Insights from the FELIX Study The FELIX study has marked a significant milestone in the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). With groundbreaking findings showing that patients achieving minimal residual disease–negative (MRD-negative) remission by next-generation sequencing (NGS) with obecabtagene autoleucel (Obe-Cel) enjoyed improved … Read more